We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-2.98%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.33B
AUM Growth
-$428M
Cap. Flow
-$106M
Cap. Flow %
-2.44%
Top 10 Hldgs %
30.21%
Holding
157
New
4
Increased
80
Reduced
15
Closed
21

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$22.8M
2
XLO icon
Xilio Therapeutics
XLO
+$20.3M
3
AURA icon
Aura Biosciences
AURA
+$18M
4
CMPX icon
Compass Therapeutics
CMPX
+$17.7M
5
AGL icon
Agilon Health
AGL
+$10.2M

Top Sells

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$49M
2
ALLK
Allakos
ALLK
+$32.4M
3
AVIR icon
Atea Pharmaceuticals
AVIR
+$26.3M
4
BOLT icon
Bolt Biotherapeutics
BOLT
+$20.9M
5
OSH
Oak Street Health, Inc.
OSH
+$18.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.41%
2 Consumer Staples 1.28%
3 Industrials 0.73%
4 Financials 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
101
Spyre Therapeutics
SYRE
$9.29B
$7.49M 0.17%
63,092
– –
EPIX
102
DELISTED
ESSA Pharma
EPIX
$7.26M 0.17%
511,044
+3,000
+0.6% +$33.4K
SPRB
103
Spruce Biosciences
SPRB
$127M
$7.24M 0.17%
21,636
+68
+0.3% +$20.2K
LONA
104
LeonaBio Inc
LONA
$70.5M
$7.2M 0.17%
55,225
– –
DSGN icon
105
Design Therapeutics
DSGN
$897M
$7.18M 0.17%
335,247
+1,197
+0.4% +$20.6K
PHAS
106
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$6.74M 0.16%
2,581,299
+737,535
+40% +$2.23M
DAWN
107
DELISTED
Day One Biopharmaceuticals
DAWN
$6.44M 0.15%
381,939
+5,500
+1% +$113K
FATE icon
108
Fate Therapeutics
FATE
$322M
$6.44M 0.15%
110,000
– –
APLT
109
DELISTED
Applied Therapeutics
APLT
$6.28M 0.15%
701,680
– –
RYTM icon
110
Rhythm Pharmaceuticals
RYTM
$7.95B
$6.26M 0.14%
627,180
+15,000
+2% +$169K
KNTE
111
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$6.02M 0.14%
339,846
+6,860
+2% +$145K
INZY
112
DELISTED
Inozyme Pharma
INZY
$5.92M 0.14%
868,466
+18,451
+2% +$159K
CGEN icon
113
Compugen
CGEN
$221M
$5.55M 0.13%
1,289,990
+6,200
+0.5% +$33.5K
THRX
114
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$5.54M 0.13%
+437,329
New +$6.6M
GMDA
115
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$5.47M 0.13%
2,154,300
+6,900
+0.3% +$22.7K
PRLD icon
116
Prelude Therapeutics
PRLD
$385M
$4.59M 0.11%
368,959
+6,600
+2% +$107K
FOCL
117
EDAP TMS S.A.
FOCL
$228M
$4.56M 0.11%
760,900
– –
TPST icon
118
Tempest Therapeutics
TPST
$16.6M
$4.35M 0.1%
63,358
+39,499
+166% +$5.44M
FUSN
119
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$3.96M 0.09%
948,327
– –
FSTX
120
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$3.77M 0.09%
751,889
-302,343
-29% -$1.82M
TLPH icon
121
Talphera
TLPH
$73.2M
$3.54M 0.08%
316,295
+125,325
+66% +$1.91M
BLSA
122
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.03M 0.07%
309,000
– –
STTK icon
123
Shattuck Labs
STTK
$682M
$2.67M 0.06%
313,499
– –
JYAC
124
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$2.02M 0.05%
206,200
– –
PSTX
125
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$1.97M 0.05%
289,754
– –
2 3 4
5
6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Rock Springs Capital Management held 157 positions worth $4.33B, down 9% from $4.76B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rock Springs Capital Management's Q4 2021 filing shows 4 new, 80 increased, 15 reduced and 21 closed positions. Its largest new stake was Xilio Therapeutics: 85,078 shares worth $19.1M. The largest sale was Teleflex, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q4 2021 buy was Xilio Therapeutics: 85,078 shares worth $19.1M.
  • Rock Springs Capital Management added most to Baxter International in Q4 2021, an estimated $22.8M increase.
  • Rock Springs Capital Management's biggest Q4 2021 reduction was Travere Therapeutics, cutting an estimated $15.4M.
  • Rock Springs Capital Management fully exited Teleflex in Q4 2021, selling an estimated $49M.
  • Rock Springs Capital Management's ten largest holdings make up 30% of its $4.33B portfolio in Q4 2021.
  • Rock Springs Capital Management opened 4 new positions and closed 21 in Q4 2021.
  • Rock Springs Capital Management's portfolio value fell 9% quarter-over-quarter to $4.33B.

Based on Rock Springs Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.